1. 科技部，国家重点研发计划“干细胞及转化研究”，2019YFA0110803，靶向血液系统的离体基因治疗研究，2019-09至2023-12，663万元，在研，研究骨干

2. 国家自然科学基金委员会，重大项目，81890992，白血病形成及其在药物作用下的细胞异质性研究，2019-01至2023-12，392万元，在研，研究骨干

3. 中国医学科学院中央级公益性科研院所基本科研业务费青年医学人才奖励项目，2018RC310019,利用CRISPR/Cas9文库筛选技术和多组学测序 技术探索儿童急性髓系白血病复发耐药机制，2018.10-2019.09，50万元，在研，主持

4. 国家自然科学基金面上，81770175，PDGFRB重排协同IKZF1突变在Ph-like ALL发生及耐药中作用机制的研究, 2018.01-2021.12, 53万元，在研，主持

5. 北京协和医学院“中央高校基本科研业务费”，3332018190，AGGF1-PDGFRB在Ph-like B-ALL发生及TKI耐药中作用和机制的研究（滚动项目）, 2018.01-2018.12, 25万元，结题，主持

6. 北京协和医学院“协和青年基金”，3332016091，AGGF1-PDGFRB在Ph-like B-ALL发生及TKI耐药中作用和机制的研究, 2016.04-2018.03, 15万元，结题，主持

7. 国家自然科学基金青年项目，81400137，组蛋白甲基化复合物PRC2在ETP T-ALL中作用的研究，2015/01-2017/12，23万元，结题，主持

1. Li, Benshang* ; Brady, Samuel W*. ; Ma, Xiaotu* ; Shen, Shuhong* ; Zhang, Yingchi*（共同第一作者） ; Li, Yongjin ; Szlachta, Karol; Dong, Li; Liu, Yu; Yang, Fan; Wang, Ningling; Flasch, Diane A.; Myers, Matthew A.; Mulder, Heather L.; Ding, Lixia; Liu, Yanling; Tian, Liqing; Hagiwara, Kohei; Xu, Ke; Zhou, Xin; Sioson, Edgar; Wang, Tianyi; Yang, Liu; Zhao, Jie; Zhang, Hui; Shao, Ying; Sun, Hongye; Sun, Lele; Cai, Jiaoyang; Sun, Hui-Ying; Lin, Ting-Nien; Du, Lijuan; Li, Hui; Rusch, Michael; Edmonson, Michael N.; Easton, John; Zhu, Xiaofan; Zhang, Jingliao; Cheng, Cheng; Raphael, Benjamin J.; Tang, Jingyan; Downing, James R.; Alexandrov, Ludmil B.; Zhou, Bin-Bing S. ; Pui, Ching-Hon ; Yang, Jun J. ; Zhang, Jinghui ; Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia , Blood （IF=16.562）, 2020, 135(1): 41-55.    

2. Zhang J*, Zhang Y*（共同第一作者和共同通讯作者）, Zhang M, Liu C, Liu X, Yin J, Wu P, Cheng X, Yang W, Zhang L, Guo Y, Zou Y, Chen Y, Cao Y, Cheng T, Zhu X.FLT3 pathway is a potential therapeutic target for PRC2 mutated T cell acute lymphoblastic leukemia. Blood （IF=16.562）. 2018 Dec 6;132(23):2520-2524.

3. Zhang Y*, Gao Y*, Zhang H*, Zhang J, He F, Hnízda A, Qian M, Liu X, Gocho Y, Pui CH, Cheng T, Wang Q, Yang JJ, Zhu X, Liu X. PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. Blood （IF=16.562）. 2018 May 17;131(20):2256-2261.

4. Zhan D*, Zhang Y*（共同第一作者）, Xiao P*, Zheng X, Ruan M, Zhang J, Chen A, Zou Y, Chen Y, Huang G, Hu S, Wang QF, Zhu X. Whole exome sequencing identifies novel mutations of epigenetic regulators in chemorefractory pediatric acute myeloid leukemia. Leuk Res. 2018 Feb;65:20-24.

5. Zhang Y*, Zhang J*, An W*, Wan Y, Ma S, Yin J, Li X, Gao J, Yuan W, Guo Y, Engel JD, Shi L, Cheng T, Zhu X. Intron 1 GATA site enhances ALAS2 expression indispensably during erythroid differentiation. Nucleic Acids Res （IF=11.147）. 2017 Jan 25;45(2):657-671.

6. Zhang Y*, Peng L*, Hu T*, Wan Y, Ren Y, Zhang J, Wang X, Zhou Y, Yuan W, Wang Q, Cheng T, Zhu X. La-related protein 4B maintains murine MLL-AF9 leukemia stem cell self-renewal by regulating cell cycle progression. Exp Hematol. 2015 Apr;43(4):309-318.

7. Zhang Y*, Hu T*, Hua C*, Gu J, Zhang L, Hao S, Liang H, Wang X, Wang W, Xu J, Liu H, Liu B, Cheng T, Yuan W. Rictor is required for early B cell development in bone marrow. PLoS One. 2014 Aug；9(8):e103970. 

8. Zhang Y*, Hua C, Cheng H, Wang W, Hao S, Xu J, Wang X, Gao Y, Zhu X, Cheng T, Yuan W. Distinct sensitivity of CD8+CD4- and CD8+CD4+ leukemic cell subpopulations to cyclophosphamide and rapamycin in Notch1-induced T-ALL mouse model. Leukemia Res. 2013 Nov;37 (11):1592-601.